#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2936	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2716	258.6	0	.	n	.	0	C199T	SNP	199	199	C	711	711	T	247	T,C	124,97	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2936	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2716	258.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1962	1962	T	366	T,C	331,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2936	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2716	258.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1696	1696	C	384	C	353	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4125	300.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1873	1873	A	358	A	332	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4125	300.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2507	2507	C	368	C,A	343,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4125	300.2	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2581	2581	G	368	G,T	333,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4125	300.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3133	3133	C	381	C,A	361,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	310	folP	855	855	100.0	folP.l15.c17.ctg.1	2177	33.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1238	1240	AGC	42;43;43	A;G;C	41;42;42	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	792	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	4057	47.0	1	SNP	p	S91F	1	.	.	271	273	TTC	877	879	TTC	46;46;46	T;T;C,T,A	42;41;41,1,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	792	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	4057	47.0	1	SNP	p	D95G	1	.	.	283	285	GGC	889	891	GGC	50;49;49	G,T;G;C	47,1;46;42	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	792	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	4057	47.0	1	SNP	p	G95N	0	.	.	283	285	GGC	889	891	GGC	50;49;49	G,T;G;C	47,1;46;42	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	264	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1941	32.9	1	SNP	p	G45D	0	.	.	133	135	GGC	835	837	GGC	63;63;63	G;G;C	55;55;53	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	180	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1488	27.6	0	.	n	.	0	A197.	DEL	197	197	A	938	938	A	51	A	47	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	708	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3357	51.4	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1597	1599	GTC	78;77;77	G;T,G;C	73;71,1;71	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	708	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3357	51.4	1	SNP	p	D86N	0	.	.	256	258	GAC	703	705	GAC	53;54;55	G,T;A,C;C	38,1;29,1;39	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	708	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3357	51.4	1	SNP	p	S87R	1	.	.	259	261	CGT	706	708	CGT	56;56;60	C;G;T	47;34;49	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	708	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3357	51.4	1	SNP	p	R87W	0	.	.	259	261	CGT	706	708	CGT	56;56;60	C;G;T	47;34;49	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	708	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3357	51.4	1	SNP	p	R87I	0	.	.	259	261	CGT	706	708	CGT	56;56;60	C;G;T	47;34;49	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	708	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3357	51.4	1	SNP	p	S88P	0	.	.	262	264	TCC	709	711	TCC	60;60;60	T;C,T;C	51;54,1;53	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	616	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3376	43.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1716	1718	TGC	45;45;46	T;G;C	36;38;37	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	616	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3376	43.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1926	1928	GGC	40;41;41	G,T;G,T;C	37,1;39,1;39	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1512	1514	GCA	75;77;76	G;C;A	67;64;63	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1515	1517	ATC	76;76;76	A;T,G;C	63;66,1;68	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1527	1529	GTG	74;74;74	G;T,G;G	65;64,1;65	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1527	1529	GTG	74;74;74	G;T,G;G	65;64,1;65	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2031	2033	ACC	54;54;53	A;C;C	43;43;45	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2085	2087	GCG	46;46;46	G,T;C,G;G	38,1;37,1;36	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2085	2087	GCG	46;46;46	G,T;C,G;G	38,1;37,1;36	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2208	2210	GGC	56;58;58	G;G,T;C,T,G	54;54,1;53,1,1	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2217	2219	GGC	52;52;52	G;G;C,G	48;43;32,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2508	55.9	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2235	2237	TCG	50;51;51	T,G;C,A;G	31,1;40,1;46	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	852	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3683	54.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1924	1926	CCG	63;64;65	C;C;G,C	55;60;45,2	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	268	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2304	28.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	776	776	C	20	C	17	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	476	478	GAA	59;58;58	G,A;A,C;A	54,1;52,1;53	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	T106I	NONSYN	316	318	ACC	680	682	ATC	67;67;68	A;T;C	61;61;61	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	764	766	GAT	67;71;72	G;A;T	58;64;61	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	887	889	TCA	60;59;59	T;C;A	53;52;54	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	Y211F	NONSYN	631	633	TAC	995	997	TTC	49;49;49	T,G;T,A;C,T	48,1;47,1;48,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1016	1018	GTC	52;52;52	G;T;C,T	51;51;50,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	P219L	NONSYN	655	657	CCT	1019	1021	CTC	52;52;52	C;T;C	51;51;51	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	A246V	NONSYN	736	738	GCA	1100	1102	GTA	56;56;56	G;T;A	55;55;55	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1346	1348	GCA	64;64;62	G;C;A	61;60;59	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	1	SNP	p	G120K	1	.	.	358	360	AAG	722	724	AAG	69;69;71	A,C;A;G	62,1;63;65	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	1	SNP	p	A121D	1	.	.	361	363	GAC	725	727	GAC	71;71;71	G,T;A;C	64,1;66;66	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	390	porB1b	1047	1047	98.95	porB1b.l15.c30.ctg.1	1618	52.6	1	SNP	p	D121N	0	.	.	361	363	GAC	725	727	GAC	71;71;71	G,T;A;C	64,1;66;66	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1476	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5416	65.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2238	2240	CAT	74;73;73	C;A;T	71;71;71	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	242	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1610	37.0	1	SNP	p	V57M	1	.	.	169	171	ATG	864	866	ATG	79;79;80	A;T;G	73;75;76	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
